Prevalence of Alzheimer's Disease Pathology in the Community – The HUNT Study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
The prevalence of Alzheimer’s disease neuropathological changes (ADNC), the leading cause of cognitive impairment, remains uncertain. Recent blood-based biomarkers enable scalable assessment of ADNC. Here, we measured phosphorylated tau at threonine 217 in 11,486 plasma samples from a population-based cohort of individuals >57 years. The prevalence of ADNC increased with age, from 10% in people 58-69.9 years to 64.9% in those over 90. In the 70+ population, 11.4% had preclinical AD, 10.8% had prodromal AD, and 7.4% had AD dementia. Furthermore, among those 70+, ADNC was present in 57.7% of people with dementia, in 31% of those with mild cognitive impairment and in 22.6% of the cognitively unimpaired group. Our findings suggest a higher prevalence of AD dementia in older individuals and a lower prevalence of preclinical AD in younger groups than previously estimated. Ten percent of the 70+ group met the present eligibility criteria for monoclonal antibody AD treatments.
